PRL and prolactin-producing pituitary gland adenoma: The therapeutic targets in prolactinomas are to normalize PRL, reduce tumour size, resolve clinical manifestations of hyperprolactinaemia and of mass effects (particularly visual disturbances) and prevent progression or recurrence of the tumour [25,74].